Objective: To examine the role of atrial natriuretic peptide (ANP) and cyclic GMP in the regulation of angiotensin converting enzyme (ACE) in cultured human endothelial cells. Methods: Cultured endothelial cells from human umbilical veins (HUVEC) were treated with ANP (0.3-30 nM), 8-Br-cGMP (1-100 mM), Rp-8-Br-PET-cGMPS (1 mM), or the phosphodiesterase inhibitors, zaprinast (10-100 mM), dipyridamole (1-10 mM), or isobutyl methyl xanthine (IBMX, 0.1-0.5 mM). ACE amounts were measured by inhibitor binding assay and cellular cGMP levels by radioimmunoassay. Results: ANP caused a dose dependent increase in ACE measured in intact endothelial cell culture. The stimulatory effect of ANP was blocked by Rp-8-Br-PET-cGMPS, a protein kinase G inhibitor. The cyclic GMP analog, 8-Br-cGMP and the cyclic GMP specific phosphodiesterase inhibitor, zaprinast, both increased ACE. Increase of ACE was also caused by nonspecific phosphodiesterase inhibitors, dipyridamole and IBMX. Intracellular cGMP levels were shown to increase by ANP, and phosphodiesterase inhibitors. Conclusions: These data suggest that cGMP is an intracellular mediator regulating ACE and that ANP induced increase of ACE is mediated via a cGMP dependent mechanism.
Introduction
reducing experimental atherogenesis [3] and in the reduction of left ventricular hypertrophy of hypertensive patients Angiotensin converting enzyme (ACE) is a dipeptidyl [4] . Bradykinin has vascular effects through stimulation of carboxypeptidase widely distributed on the luminal surface nitric oxide production [5] . Accumulation of endogenous of vascular endothelium. ACE catalyzes the proteolytic bradykinin is involved in the vascular effects of ACE cleavage of angiotensin I to angiotensin II (AII) and has inhibitors in humans [6] . However, the exact contribution bradykinin degrading activity [1] . Thus, ACE participates of bradykinin to the beneficial effects of ACE inhibition on in the control of vascular resistance by generating AII and cardiovascular hypertrophy is still uncertain [7] . degrading bradykinin. AII also acts as a vascular growth Regulation of ACE is only partly understood. A number factor participating in angiogenesis, vascular remodelling of compounds have been reported to increase ACE expresand response to vascular wall injury [2] . As a regulator of sion or activity in cultured endothelial cells. Those com-AII production ACE may have an important role in pounds include endothelin- where [15] .
I-351A is specifically bound to ACE plemented with 20% fetal calf serum (Gibco), 20 mg / ml [15, 16] . Thus, bound label is displaced from ACE binding endothelial cell growth supplement (Sigma), 12 U / ml by unlabeled lisinopril (0.125-2 ng / ml, Merck, Sharp and heparin (Sigma), 100 U / ml G-penicillin, 100 mg / ml Dohme), and ramiprilate (0.125-2.5 ng / ml, Hoechst, streptomycin (Gibco) and 2 mM L-glutamine (Gibco) at Frankfurt am Main, Germany). After incubation of 378C in humidified 5% carbon dioxide in air. The cellsH UVECs with test substances cell monolayers were were detached with 0.125% trypsin-0.02% Na EDTA 2 washed with PBS. Typically, 10 000 cpm of label per well solution (Gibco) and subcultured on 48-well cell culture in culture medium was added to HUVEC's cultured on plates (Costar) coated with 0.2% gelatin solution.
48-well plates. Following incubation at 378C for 2 h, cells were washed twice with PBS, then detached with 0.1 M 2.2. Experimental design NaOH, and counted in a gamma counter.
Confluent subcultures (at passages 1-2) were incubated 2.5. Statistical evaluation for 24 hours with Medium 199 supplemented with 5% fetal calf serum with or without the following substances added
Results are expressed as mean 6 SEM of six replicate in one dose: Atrial natriuretic peptide (ANP, 0.3-30 nM), determinations from three to four separate experiments. Rp-8-Br-PET-cGMPS (1 mM), 8-bromoguanosine Student's t-test for paired or unpaired observations waś 3:5-cyclic monophosphate (8-Br-cGMP, 1-100 mM), zapapplied. rinast (1-100 mM), dipyridamole (1-10 mM), 3-isobutyl-1-methylxanthine (IBMX, 0.1-0.5 mM), or cycloheximide (0.2-2 mg / ml). Cell cultures were preincubated with Rp-3. Results 8-Br-PET-cGMPS for 15 min before adding ANP and with cycloheximide for 30 min before adding test substances.
3.1. Assay characteristics After incubation time ACE assay was performed as described below. The effect of test substances on cellular Membrane bound ACE could be determined in intact viability and growth were tested by a CellTiter 96 cell endothelial cells grown on 48-well plates. The amount of proliferation / cytotoxicity assay kit (Promega, Madison, ACE used as a measure of ACE throughout this report is Wis,USA). Rp-8-Br-PET-cGMPS was from Biolog Life expressed as a measure of the quantity of bound ACE displacement of labeled ACE inhibitor from endothelial cells with lisinopril and ramiprilate ( Fig. 1 ) and the Scatchard analysis (Fig. 2) show the specificity of the IBA assay. Non-specific binding was ,1%.
Stimulation of ACE
Incubation of endothelial cells with human ANP (0.3-30 nM) dose dependently increased ACE (Fig. 3a) . The stimulatory effect of ANP was blocked by protein kinase G inhibitor, Rp-8-Br-PET-cGMPS (Fig. 3b) . cGMP analog, 8-Br-cGMP (1-100 mM), dose dependently increased ACE (Fig. 4) . The selective cGMP phosphodiesterase, type stimulatory effects of all the test substances were blocked by cycloheximide (0.2 and 2 mg / ml) (data not shown) indicating that de novo protein synthesis was needed.
Stimulation of cGMP
Enhanced intracellular cGMP levels were measured after 30 min incubation time with ANP (3-30nM), and the phosphodiesterase inhibitors zaprinast (10-100 mM), IBMX (0.1-0.5mM), and dipyridamole (10-100 mM) ( Table 1 ). of inducing ACE were within the range observed in congestive heart failure [17] , and may thus be considered biologically relevant. ANP acts via two main types of specific receptors; guanylate cyclase linked receptors and a receptor thought to have a clearance function. Binding of ANP to guanylate cyclase linked receptors leads to increased intracellular cGMP levels [18] . The intracellular action of ANP involves increased cGMP levels.
Discussion
To study the role of cGMP as an intracellular regulator of ACE an analog of cGMP, 8-Br-cGMP was used. 8-BrcGMP increased ACE in intact HUVEC monolayers. Increase of ACE was also observed using a selective cGMP phosphodiesterase inhibitor, zaprinast, which increases intracellular cGMP levels by inhibiting breakdown of cGMP. Further, the cGMP antagonist, RP-8-Br-PETcGMPS, inhibited ACE induction by ANP. These data suggest that cGMP is an intracellular regulator of ACE and that induction of ACE by ANP involves elevated intracellular cGMP levels. No effect on basal ACE amount was observed with the cGMP antagonist. This suggests that ACE is insensitive to modulation by low levels of cGMP spontaneously produced by endothelial cells.
In contrast to these observations, inhibition of ACE activity by ANP in cultured bovine aortic endothelial cell line has been reported [19] . This controversy may be explained by different sources of cells used. Conflicting inhibitors may partly be a result of increased intracellular diesterases are possible regulators of ACE.
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In summary, the present data suggest that cGMP is a 
